EWTX Edgewise Therapeutics, Inc.

3d ago, source: Seeking Alpha

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally ...

European agency grants orphan status to Edgewise drug

1d ago, source: BizWest

The European Medicines Agency has granted orphan drug designations to one of Edgewise Therapeutics muscular dystrophy drugs.

Edgewise gets EU orphan drug status for muscular dystrophy drug

on MSN ago, source:

Edgewise Therapeutics (EWTX) has received orphan drug designation from EU regulators for sevasemten in the treatment of ...

Edgewise Therapeutics Earns ‘Buy’ Rating from Joseph Schwartz on Strong Clinical Data and Promising Drug Prospects

8d ago, source:

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on EWTX stock, giving a Buy rating yesterday. Joseph Schwartz has ...

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

1mon ago, source: Stockhouse

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to ...

Edgewise's sevasemten earns EU orphan drug status

2d ago, source: Investing

BOULDER, Colo. - Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle diseases, announced today that the European Medicines Agency (EMA) has granted Orphan Drug ...

Edgewise phase Ib data promising in Becker muscular dystrophy

10d ago, source: BioWorld

With no drugs approved by the U.S. FDA for treating Becker muscular dystrophy, Edgewise Therapeutics Inc. reported positive ...

Edgewise Therapeutics, Inc.

19d ago, source: CNN

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

Edgewise Therapeutics Inc EWTX

2mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edgewise Therapeutics Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Edgewise Therapeutics Inc EWTX

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edgewise Therapeutics Inc.

23d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...